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Abstract
Introduction The goal of pharmacological prophylaxis of
chemotherapy-induced nausea and vomiting (CINV) should
be the elimination of both nausea and vomiting symptoms
during all planned chemotherapy cycles. The aim of this
study was to assess the efficacy of a single dose of palono-
setron and dexamethasone to prevent CINVand to guarantee
an adequate food intake (FI) in patients receiving several
cycles of multiple day-based chemotherapy (MD-CT).
Methods Patients with advanced cancer but without a com-
promised nutritional status (bone mass index≥18.5) were
treated with 0.25 mg palonosetron plus 20 mg dexamethasone
before MD-CT. The MD-CT regimen was either epirubicin
plus ifosfamide or paclitaxel plus cisplatin and ifosfamide.
Nausea, vomiting, and FI were monitored in a 7-day diary.
Complete response (CR: no vomiting and no rescue therapy)
was the primary endpoint, while complete control (CC: CR
and no more than mild nausea) and the evaluation of FI were
secondary endpoints. The endpoints were evaluated during
the overall timescale (0–168 h) of the chemotherapy regimen.
Results Fifty patients were enrolled, 80% of whom achieved
CR and 78% achieved CC. During the six chemotherapy
cycles, CR and CC ranged from 76% to 88% and from 62%
to 88%, respectively. Moreover, patients with CR had a sig-
nificantly (p<0.0001) higher weekly food intake compared
with patients not achieving CR.
Conclusions This trial was the first to assess the efficacy of
palonosetron and dexamethasone for the prevention of both
nausea and vomiting in patients receiving multiple cycles of
MD-CT. In this trial, the ability of patients to intake an
adequate amount of food each week was correlated with
nausea, thus providing clinicians with an objective parameter
for the measurement of the effects of nausea. A single dose of
palonosetron and dexamethasone was able to prevent CINV in
most patients receiving 3 days of chemotherapy during all
planned chemotherapy cycles.
Keywords Chemotherapy-induced nausea and vomiting
(CINV) .Food intake .Multipledaychemotherapy .Multiple
cycles . Palonosetron
Introduction
Prevention, rather than treatment, is the principal aim of
antiemetic prophylaxis in patients undergoing chemothera-
py [1]. Control of chemotherapy-induced nausea and vomit-
ing (CINV) is necessary to maintain an adequate quality of
life and to guarantee the completion of treatment during all
planned chemotherapy cycles [1]. Few studies have assessed
the efficacy of antiemetic prophylaxis over multiple chemo-
therapy cycles [2–4]. It is also well-known that patients who
are not adequately protected from nausea and vomiting
during the first chemotherapy cycle are at a higher risk of
developing anticipatory emesis in subsequent cycles [5]. As
a consequence, CINV control becomes more difficult.
Risk factors for CINVare both patient- and chemotherapy-
related: female gender, young age, motion sickness, and no
alcohol consumption are patient risk factors while the
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emetogenic potential of the chemotherapy drug and multiple
day (MD) and/or high dose administration are chemotherapy-
related risk factors [6, 7].
Patients treated with MD chemotherapy (MD-CT) are at
risk from CINV throughout the entire treatment period because
continuous daily emetogenic stimuli make antiemetic prophy-
laxis quite problematic [7]. For CINV prophylaxis in patients
receiving MD-CT, antiemetic guidelines suggest the use of a
single dose of palonosetron, a second-generation 5-HT3 recep-
tor antagonist (5-HT3RA), instead of multiple daily doses of
first generation 5-HT3RAs (ondansetron, granisetron, tropise-
tron), with the addition in both cases of dexamethasone [8, 9].
Palonosetron demonstrated superior results in preventing
CINV in high (HEC) and moderately (MEC) emetogenic
chemotherapy compared with first-generation 5-HT3RAs
[10–14]. Indeed, besides controlling vomiting, palonosetron
in combination with dexamethasone, as compared with other
antiemetic drugs [14–16], is also better at controlling nausea
and can guarantee an adequate caloric intake during the 7-day
period following the first chemotherapy cycle [17]. In a pre-
vious study, we proposed the use of a nutritional diary for the
measurement of caloric intake, to more objectively define the
impact of nausea on the patient’s quality of life. In our hands,
this tool provided an objective measurement of the improve-
ment of patient’s quality of life induced by the pharmacolog-
ical prophylaxis.
The antiemetic efficacy of palonosetron has routinely
been assessed during the first chemotherapy cycle [5,
7]; however, no published clinical trial has evaluated its
prospective efficacy over the course of the entire patient
treatment plan. However, a recent survey assessed the
safety of palonosetron administered over multiple cycles
of 1-day MEC and HEC, demonstrating that it was well
tolerated, with no unexpected treatment adverse events
in later cycles [18].
The aim of this study was to therefore assess the efficacy
of a single dose of palonosetron and dexamethasone to
prevent CINV, in order to ensure adequate food intake, in
patients receiving numerous cycles of MD-CT.
Patients and methods
The study presented here describes a prospective, uncon-
trolled trial conducted in the Oncology Department of the
Vito Fazzi Hospital in Lecce, Italy. The study was approved
by the local ethic committee, and all patients signed the
informed consent form.
Eligible cancer patients receiving MD-CT were enrolled
in the study. The main inclusion criteria were: age >18 years
old; ECOG 0–1; normal renal and liver function; no uncon-
trolled vomiting; and absence of intestinal obstruction, peri-
tonitis, serious mucositis, and infections.
A nutritional assessment was performed for each patient,
and all eligible patients were required to have a moderate or
well-nourished nutritional status according to the subjective
global assessment (SGA). In addition, a bone mass index
(BMI) ≥18.5 was required.
The MD-CT regimen was either EPI-IFO (epirubicin plus
ifosfamide) or TIP (paclitaxel plus cisplatin and ifosfamide).
Refer to Table 1 for the study treatment flow chart.
Patients received an antiemetic treatment of a single
palonosetron bolus, 0.25 mg iv, over 30 s, and a single dose
of dexamethasone, 20 mg, both administered 30 min prior to
the administration of chemotherapy. The same antiemetic
therapy was administered before each planned chemotherapy
cycle.
All patients maintained a diary from day 1 until day
7. The study diary was organized with both an emesis
and a nutrition-specific section, as reported in a previ-
ous publication [17]. In the emesis section, patients
recorded each episode of vomiting, nausea experienced,
and any use of rescue medication. In the nutritional
section, patients had to quote their daily food intake,
the time food was consumed, and the amount of each
portion eaten. The amount of portions was quantified
using pictures of standard portions included in the diary.
The diary had to be completed from day 1 (day of first
chemotherapy administration) until day 7 (168 h after
chemotherapy administration). On day 8, the patient
returned the diary to the investigator and discussed with
Table 1 Chemotherapy regimens, antiemetic prophylaxis, and study
assessments
Variable D1 D2 D3 D4 D5 D6 D7
Chemotherapy regimens
EPI-IFO
Epirubicin 60 mg/m2 X
Ifosfamide 3 g/m2 X X X
TIP
Paclitaxel 175 mg/m2 X
Cisplatin 75 mg/m2 X
Ifosfamide 1,5 g/m2 X X X
Antiemetic prophylaxis
Palo 0.25 mg X
Dex 20 mg X
Study evaluations
CINV X X X X X X X
FI X X X X X X X
Abbreviations: D day, Palo palonosetron, Dex dexamethasone, CINV
chemotherapy-induced nausea and vomiting, FI food intake, EPI-IFO
epirubicine plus ifosfamide, TIP paclitaxel, cisplatin, and ifosfamide
3242 Support Care Cancer (2012) 20:3241–3246
him all entries regarding CINV information. The nutri-
tional expert then reviewed and discussed all nutritional
data.
All patients were monitored for a maximum of six che-
motherapy cycles.
Endpoints
Primary and secondary endpoints were evaluated during
the 7 days following the first chemotherapy administra-
tion: overall phase (0–168 h). The primary endpoint of
the study was the percentage of patients with complete
response (CR), defined as no vomiting and no use of
rescue medication. Secondary endpoints were: complete
control (CC), totally control (TC), and impact of nausea
severity and CR on weekly food intake. CC was defined
as no vomiting, no rescue medication, and no more than
mild nausea; TC was defined as no vomiting, no rescue,
and no nausea. Severity of nausea was evaluated using
a four-point Likert scale ranging from 0 (none) to 3
(severe). Among the CC patients, the impact of residual
nausea on weekly food intake was evaluated, comparing
the CC patients with mild nausea versus the CC patients
with no mild nausea.
All patients who started the first chemotherapy cycle
were evaluated throughout all subsequent cycles (maximum
six cycles).
Treatment safety was evaluated during all chemother-
apy cycles, and all adverse events were recorded and
graded according to the common terminology criteria
for adverse events (CTCAE) described by the National
Cancer Institute, version 4.0. (http://ctep.cancer.gov/
forms/CTCAEv4.pdf).
Statistical analysis
The demographic and clinical–pathological characteristics
were summarized by means of descriptive statistics. In
general, absolute and relative frequencies were employed
to summarize qualitative variables, while arithmetic mean,
standard deviation (SD), median, and range were used to
summarize quantitative data.
Main and sub-group comparisons were tested using one-
way analysis of variance for continuous variables. The rela-
tionship between weekly intake (kilocalories) and nausea
scores was investigated by means of linear correlation anal-
ysis. Due to the supportive and exploratory nature of these
comparisons, no adjustments for multiplicity were per-
formed for the multiple comparisons across cycles, end-
points, and sub-groups. Differences were considered to be
statistical significant for two-tailed p values≤0.05. All sta-
tistical computations were carried out using the SAS system
version 9.1.3.
Results
Between July 2008 and January 2010, 50 consecutive
patients were enrolled and evaluated. Most participants were
female (82%), chemo-naïve (74%), with a diagnosis of soft
tissue sarcoma (52%). All patients received at least two
consecutive chemotherapy cycles, and half (50%) complet-
ed the six planned chemotherapy cycles. None of the
patients were severely malnourished; the majority had an
adequate appetite (median apVAS 7) and a median BMI of
26 (range, 18.5–30.5). Baseline patient characteristics and
nutritional status are reported in Table 2.
Table 2 Baseline patient characteristics and nutritional status
Number of patients, 50
Age, years










Previous Treatment % (N)
Naive 74 (37)
Not naive 26 (13)
Chemotherapy regimen % (N)
Ifosfamide–epirubicin regimens 68 (34)
Cisplatin-based regimen >50 mg/mq 32 (16)







Nutritional status at baseline
BMI value
Median (range) 26 (18.5–30.5)
apVAS value
Median (range) 7 (3–10)
SGA, % (N)
A, well nourished 84 (42)
B, moderately nourished 16 (8)
C, severely nourished 0
BMI body mass index, apVAS visual analogue scale to assess appetite,
SGA subjective global assessment
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During the six consecutive chemotherapy cycles CR, CC,
and TC ranged from 76% to 88%, from 62% to 88% and
from 54% to 80%, respectively (Fig. 1). The severity of
nausea had a direct impact on food intake (R200.72)
(Fig. 2). The percentage of emesis-free patients was 76%
(38/50) during the first chemotherapy cycle; 86% (43/50),
89.4% (42/47), 86.8% (33/38) during the second, third, and
fourth cycle, respectively; and 88% (22/25) during the final
two cycles.
The correlation between the severity of nausea and the
amount of weekly food intake remained uniform during all
subsequent chemotherapy cycles (Fig. 3). During cycles 5
and 6, no patient experienced any nausea of moderate
severity.
During all chemotherapy cycles (Table 3), CR patients
always had a significantly higher weekly food intake than
patients who experienced vomiting and/or used rescue
medication (p0<0.0001).
The impact of mild nausea on food intake was evalu-
ated in the CC population. CC patients who experienced
no nausea had a median weekly food intake ranging from
11,102 to 12,200 kcal during multiple chemotherapy
cycles, whereas CC patients with symptoms of mild nau-
sea had a median weekly food intake ranging from 8,500 to
9,800 kcal. The difference between the two groups (minimum
2,102 to maximum 2,957 kcal) was statistically signifi-
cant during all chemotherapy cycles (Table 4). None of
the patients experienced mucositis during chemotherapy
treatment.
Discussion
The elimination of vomiting and symptoms of nausea should
be the goal of antiemetic prophylaxis, not only during the first
course of chemotherapy, but also during all planned cycles [1].
Vomiting and nausea still rank among the fivemost distressing
symptoms among cancer patients receiving chemotherapy
[19, 20]. In this study, we assessed for the first time the
antiemetic efficacy of a single dose of palonosetron and dexa-
methasone in patients receiving multiple cycles of MD-CT.
For patients receiving MD-CT, the control of CINV is
more difficult to achieve due to continuous daily emetic
stimuli, especially since acute and delayed emesis may
overlap. Antiemetic guidelines for the treatment of MD-
CT suggest the administration of a 5-HT3RA once daily at
the time of chemotherapy administration and for 2–3 days
following the end of treatment. A single intravenous palo-
nosetron dose could be used instead of multiple daily doses
of old generation 5-HT3RAs [7, 8]. This was suggested
following recent clinical trials, which assessed the efficacy
of single and multiple doses of palonosetron both in onco-
logical [17, 21, 22] and hematological [23] MD-CT settings.
It has previously been demonstrated that the use of palono-
setron can also reduce the use of dexamethasone in antie-
metic prophylaxis in patients receiving MEC and AC-based
(doxorubicin and cyclophosphamide) chemotherapy [24, 25]. In
Fig. 1 Percentage of patients achieving a complete response (CR no
vomiting and no rescue medication), a complete control (CC no vomit-
ing, no rescue medication and no more than mild nausea), and total
control (TC no vomiting, no rescue, and no nausea) during the six
chemotherapy cycles
Fig. 2 Impact of nausea on food intake during six consecutive che-
motherapy cycles
Fig. 3 Impact of severity of nausea on weekly food intake during 6
consecutive chemotherapy cycles
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our trial, the administration of dexamethasone was limited to
day 1 only. The reduction of dexamethasone dosing for the
prevention of CINV is of particular clinical interest since it has
been demonstrated that side effects related to steroid use are
likely to accumulate over multiple cycles of chemotherapy [26].
The results of our study suggest that a single dose of
palonosetron plus dexamethasone can achieve a high control
of CINV during all planned MD-CT cycles, which also con-
firms the efficacy of palonosetron in maintaining an adequate
food intake during all courses. Recently, a survey identified
fatigue, appetite loss, and nausea as the most distressing
symptoms experienced by cancer patients [20]. These symp-
toms persist throughout the treatment period and are reported
earlier and more frequently by patients than clinicians. In this
survey, the cumulative incidence of moderate-to-severe nau-
sea is similar to that of moderate-to-severe appetite loss,
suggesting a strict correlation between these two adverse
events [20]. In our trial, the correlation between severity of
nausea and weekly caloric intake is maintained during all
chemotherapy cycles. The patients’ ability to enjoy a meal,
even during the week of chemotherapy administration, is
necessary to relieve symptoms and to guarantee the comple-
tion of the planned cancer treatment. The administration of
first-generation 5HT3RAs together with dexamethasone has
improved the control of vomiting, and their introduction into
routine oncology practices was a key advance, along with
other supportive care, towards a major shift in oncology care
in the ambulatory setting [27]. However, the control of nausea
still remains suboptimal and the impact of residual nausea on
patients’ health and quality of life should not be underesti-
mated. Our study (Table 4) highlighted that residual episodes
of nausea—no matter how mild—significantly affected the
patients’ nutritional status as their weekly food intake was
reduced throughout the entire chemotherapy treatment. In-
deed, the control of nausea still remains an unmet need in
cancer patients receiving chemotherapy.
The role of palonosetron in antiemetic MD-CT prophylax-
is, where acute and delayed CINV overlap, is probably
explained by its unique pharmacological properties. Palono-
setron has a longer half-life (40 h) [28] and a greater receptor
binding affinity (>30-fold) than other 5-HT3RAs [29]. More-
over, palonosetron exhibits allosteric interactions [30], trig-
gers receptor internalization, and exhibits prolonged inhibition
of receptor function [31]. Palonosetron is the only antiemetic
drug that has been demonstrated to ensure an adequate amount
of weekly food intake during all chemotherapy cycles due to
its ability to control nausea besides vomiting.
Larger and randomized studies are granted to define
the role of nausea and vomiting on ability of patients to
intake an adequate amount of food during chemotherapy
administration, both in MD- and single day-CT.
In conclusion, this study demonstrates that palonosetron
and dexamethasone are effective in the prevention of both
vomiting and nausea in patients receiving multiple day-based
chemotherapy and that this effect is sustained throughout the
entire chemotherapy treatment program.
Table 3 Amount of weekly
food intake (expressed in kilo-
calories) related to complete re-
sponse during all evaluated
chemotherapy cycles
CR complete response (no vom-
iting and no use of rescue medi-
cation), SD standard deviation, N
number of patients
Weekly kilocalories CR, yes CR, no P value
Cycle 1, mean±SD (N) 10,725±1,726.49 (38) 5,766.67±3,049.69 (12) <.0001
Cycle 2, mean±SD (N) 10,927.91±1,962.61 (43) 4,971.43±1,939.69 (7) <.0001
Cycle 3, mean±SD (N) 11,002.56±1,981.29 (39) 6,314.29±4,486.06 (7) <.0001
Cycle 4, mean±SD (N) 11,683.33±1,697.55 (33) 3,440±999 (5) <.0001
Cycle 5, mean±SD (N) 11,577.27±1,770.91 (22) 3,800±556.78 (3) <.0001
Cycle 6, mean±SD (N) 11,763.64±1,573.07 (11) 3,433.33±1,059.87 (3) <.0001
Table 4 Impact of mild nausea
on weekly food intake among
the CC population during the all
six chemotherapy cycles
Cycle Complete control Weekly kilocalories (mean) Difference (weekly kilocalories) P value
1 No nausea 11,102 2,602 0.0025
Mild nausea 8,500
2 No nausea 11,509 2,776 <0.0001
Mild nausea 8,733
3 No nausea 11,632 2,632 0.0001
Mild nausea 9,000
4 No nausea 12,002 2,102 0.0085
Mild nausea 9,900
5 No nausea 12,082 2,957 0.0010
Mild nausea 9,125
6 No nausea 12,200 2,400 0.0431
Mild nausea 9,800
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